Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc., trading under the ticker symbol VOR, is at the forefront of cell and genome engineering, specifically focusing on hematopoietic stem cells (HSCs). Headquartered in Cambridge, Massachusetts, Vor Bio aims to revolutionize the treatment of hematological cancers, particularly acute myeloid leukemia (AML). The company’s pioneering platform involves engineering hematopoietic stem cells (eHSCs) to generate healthy and functional cells with beneficial modifications. These modifications protect the blood and bone marrow from the adverse effects of antigen-targeted therapies while leaving cancer cells vulnerable.
Key Products and Innovations:
- VOR33 (Trem-cel) - Vor Bio’s lead program, a CRISPR/Cas9 genome-edited allogeneic HSC transplant that lacks the CD33 protein. This product is designed to replace standard transplants for AML patients and potentially other blood cancers.
- VCAR33ALLO - A CD33-directed CAR-T cell therapy derived from healthy transplant donor cells. This approach aims to provide more potent and durable responses in the post-transplant setting without on-target toxicity.
Recent Achievements and Collaborations:
- Secured a non-exclusive worldwide license from Editas Medicine for ex-vivo Cas9 gene-edited HSC therapies.
- Partnership with Janssen for the preclinical development of CD33-deleted allografts and their synergistic effects with Janssen's CD33-targeted immunotherapy candidate.
Clinical Trials and Research:
- VBP101 Clinical Trial - Ongoing Phase 1/2a study of trem-cel in AML patients, showing promising engraftment results and hematologic protection.
- VCAR33ALLO Clinical Trial (VBP301) - A Phase 1/2 study involving CAR-T cell therapy derived from healthy transplant donors, showing initial successful dosing and manufacturing capabilities.
Financial Updates: In its latest quarterly report, Vor Bio announced positive financial outcomes, including an extended cash runway into the second half of 2025. The company is focused on executing its clinical trials and expanding its platform to include additional innovative therapies.
Future Outlook: Vor Bio is set to present at major scientific conferences, including the American Society of Hematology (ASH) Annual Meeting, where it will share significant preclinical and clinical data. The company is also looking forward to additional data releases from its clinical trials by year-end, which could further validate their treatment system for AML.
For more updates, visit www.vorbio.com.
Vor Biopharma (Nasdaq: VOR) announced that Dr. Robert Ang, President and CEO, will participate in the Piper Sandler 33rd Virtual Annual Healthcare Conference. The conference is scheduled from November 30 to December 2, 2021. A pre-recorded presentation will be available on-demand starting November 22, 2021, at 10:00 am ET, accessible via the Investors section of Vor's website. Vor Biopharma focuses on engineering hematopoietic stem cells to improve treatments for blood cancers.
Vor Biopharma (Nasdaq: VOR) reported its Q3 2021 financial results, indicating a net loss of $18.6 million, up from $11.8 million in Q3 2020. The company is actively enrolling patients in its Phase 1/2a trial of VOR33 for AML, with initial data expected in H1 2022. VOR33 has received FDA Fast Track designation. Vor expanded its pipeline with a new multi-targeted treatment system and is progressing on its internal manufacturing facility, set to be operational in 2022. Cash and investments stood at $226 million, expected to fund operations into mid-2023.
Vor Biopharma (Nasdaq: VOR) has announced new data from its cell therapy platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), running from November 10-14, 2021, in Washington D.C. The research showcases a novel approach for treating acute myeloid leukemia (AML) using a cytokine tethered to T cells to enhance tumor cell killing. Vor also optimized a high-throughput fluorescent-protein platform for screening chimeric antigen receptor (CAR) constructs. The results aim to advance therapies targeting CD123-expressing leukemic cells.
Vor Biopharma (Nasdaq: VOR) announced participation in two virtual investor conferences featuring key executives. The Stifel 2021 Virtual Healthcare Conference will be held on November 15, 2021, at 4:00 PM ET, while the Evercore ISI 4th Annual HealthCONx Virtual Conference is scheduled for December 2, 2021, at 10:55 AM ET. Live webcasts for both events will be accessible via the company’s Investors section. Vor Biopharma focuses on engineering hematopoietic stem cells to improve treatments for blood cancers.
Vor Biopharma (Nasdaq: VOR) announced new data from its eHSC platform at the ASH 63rd Annual Meeting. The data includes the potential of CRISPR-Cas9 gene editing to knock out CD123 and CLL-1, enhancing treatment options for acute myeloid leukemia (AML) patients. Vor's research showcases multiplex genome editing of hematopoietic stem cells, promising safe and efficient gene editing for multiple blood cancer therapies. Presentations will occur from December 11-14, 2021, in Atlanta, Georgia, highlighting the advancements in CAR-T cell therapy and engraftment potential.
Vor Biopharma (Nasdaq: VOR) announced the appointment of Veit Schmelmer, Ph.D., as Senior Vice President of Program and Alliance Management. With over 25 years in biopharmaceuticals, Dr. Schmelmer will oversee critical programs and lead cross-functional teams to enhance Vor's mission in blood cancer treatment through engineered hematopoietic stem cells. His previous roles include leadership positions at Magenta Therapeutics and Takeda Pharmaceuticals. Vor continues to progress with its Phase 1/2a clinical trial of VOR33, and Dr. Schmelmer's expertise is expected to significantly benefit the company.
PureTech Health plc (PRTC) announces that its Founded Entity, Vor Biopharma (VOR), received Fast Track designation from the FDA for VOR33, an engineered hematopoietic stem cell therapy for acute myeloid leukemia (AML). VOR33, designed to protect healthy cells from anti-CD33 therapies, aims to replace standard transplants for high-risk AML patients. Vor is currently enrolling patients in its Phase 1/2a trial, with initial clinical data expected in the first half of 2022. The Fast Track designation signals FDA recognition of the urgent medical need in AML treatment.
Vor Biopharma (Nasdaq: VOR) has received Fast Track designation from the FDA for its lead engineered hematopoietic stem cell therapeutic, VOR33, targeting acute myeloid leukemia (AML). This designation underscores the therapy's potential to meet a significant unmet medical need for high-risk AML patients. VOR33 aims to protect healthy cells during anti-CD33 therapies. Vor is actively enrolling patients in its Phase 1/2a clinical trial and plans to report initial results in the first half of 2022. The Fast Track status could facilitate expedited development and regulatory review for VOR33.
Vor Biopharma (Nasdaq: VOR), a leader in cell and genome engineering, will participate in three virtual investor conferences. The events include a Fireside Chat at the Morgan Stanley Global Healthcare Conference on September 10, 2021, a presentation at the H.C. Wainwright Investment Conference from September 13-15, 2021, and a presentation at the Oppenheimer MedTech Summit on September 22, 2021. Attendees can access live webcasts and archived replays via the Company's website, enhancing investor outreach and information availability.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
What is Vor Biopharma Inc. known for?
What are the main products of Vor Biopharma Inc.?
Where is Vor Biopharma Inc. located?
What recent achievements has Vor Biopharma Inc. made?
What clinical trials are currently being conducted by Vor Biopharma Inc.?
What is the potential impact of Vor Biopharma Inc.'s platform?
How can I stay updated on Vor Biopharma Inc.'s progress?
What financial updates were provided by Vor Biopharma Inc. recently?
What upcoming milestones is Vor Biopharma Inc. expecting?
What collaborations has Vor Biopharma Inc. entered into?
